 Spains Grifols has agreed to work with the U.S. Food and Drug Administration and other agencies to gather plasma from patients who have recovered from COVID-19 and test potential therapies for the disease, the pharmaceutical firm said on Wednesday. The plasma will be processed to produce hyperimmune immunoglobins, which will then be put to pre-clinical and clinical tests to see if they can help treat the disease, Grifols said in a statement. 